Table 5.
Summary of reported adverse events among participants by study arms.
| Arm A | Arm B |
Arm C |
Arm D |
|||||
|---|---|---|---|---|---|---|---|---|
| mOPV1 + fIPV6 |
mOPV1 + fIPV10 |
mOPV1 | bOPV | |||||
| (n = 301) | (n = 295) | (n = 298) | (n = 298) | |||||
| Any adverse events (AE) | 26 | 9% | 17 | 6% | 30 | 10% | 17 | 6% |
| Fever | 1 | 0% | 1 | 0% | 1 | 0% | 4 | 1% |
| Chickenpox | 1 | 0% | 0 | 0% | 1 | 0% | 0 | 0% |
| Gastrointestinal-related | 1 | 0% | 4 | 1% | 5 | 2% | 4 | 1% |
| Meningitis | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 0% |
| Respiratory - acute | 13 | 4% | 9 | 3% | 20 | 7% | 8 | 3% |
| Respiratory - pneumonia | 9 | 3% | 6 | 2% | 8 | 3% | 2 | 1% |
| Other minor illness | 2 | 1% | 0 | 0% | 0 | 0% | 1 | 0% |
| Any serious adverse events (SAE) | 6 | 2% | 10 | 3% | 9 | 3% | 4 | 1% |
Data are n participants and % of participants in assigned arm. mOPV1 = monovalent oral poliovirus vaccine type 1. fIPV = fractional inactivated poliovirus vaccine. bOPV = bivalent oral poliovirus vaccine.